Professional Documents
Culture Documents
Keywords
Transdermal Delivery,
Plasma Concentration,
Potency,
Therapeutic Efficacy,
Adhesive,
Systemic Circulation,
Active Ingredient,
Self Contained,
Controlled Release.
ABSTRACT
Transdermal drug delivery represents one of the most rapidly advancing areas and established
itself as an integral part of novel drug delivery systems. Today about 74% of drugs are taken
orally and are found not to be as effective as desired. Drug delivery through the skin to
achieve a systemic effect without producing any fluctuations in plasma concentration of the
drug. Drugs that are given by transdermal route may enhance the potency as well as safety of
drugs. A transdermal drug delivery device (pharmaceutical preparation of varying sizes,
containing, one or more active ingredient), which provides an alternative route for
administering medication defined as self contained, discrete dosage forms which, when
applied to the intact skin, deliver the drug, through the skin at controlled rate to the systemic
circulation therefore system can improve the therapeutic efficacy and safety of the drugs.
These devices allow for pharmaceuticals to be delivered across the skin barrier. An advantage
of a transdermal drug delivery route over other types of medication delivery such as oral,
topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the
medication into the patient, usually through either a porous membrane covering a reservoir of
medication or through body heat melting thin layers of medication embedded in the adhesive.
Transdermal drug technology specialists are continuing to search for new methods that can
effectively and painlessly deliver larger molecules in therapeutic quantities to overcome the
difficulties associated with the oral route.
Copy right 2015 This is an Open Access article distributed under the terms of the Indo American journal of Pharmaceutical
Research, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
www.iajpr.com
Page
Please cite this article in press as Shubhangi Chauhan et al. Transdermal Patches: A Review on Novel Approach For Drug
Delivery. Indo American Journal of Pharm Research.2015:5(01).
531
Corresponding author
Shubhangi Chauhan
Research Scholar, Dept. of Pharmaceutics
Maharishi Arvind College of Pharmacy, Ambabari,
Jaipur, Rajasthan, India
angelshubh@gmail.com
91-8107385494
INTRODUCTION(1,2)
Drugs administered in the conventional dosage forms usually produce large range in fluctuations in plasma drug
concentrations leading to undesirable toxicity or poor effectiveness. These factors as well as other factors such as repetitive dosing and
unpredictable absorption, led to the concept of the controlled drug delivery system or therapeutic system. A dosage form that releases
one or more drugs continuously in a predetermined pattern for a fixed period of time, either systemically or to a specified target organ
is a controlled drug delivery system. The primary objectives of controlled drug delivery are to ensure safety and to improve efficacy of
drugs as well as patient compliance. This is achieved by better control of plasma drug levels and less frequent dosing. The most
common, form of delivery of drugs is the oral route. It has the notable advantage of easy administration, but also have significant
drawbacks namely poor bioavailability due to hepatic metabolism (first pass) and the tendency to produce rapid blood level spikes
(both high and low), leading to a need for high and or frequent dosing, which can be both cost prohibitive and inconvenient. To
overcome these difficulties there was a need for the development of new drug delivery system; which can improve the therapeutic
efficacy and safety of drugs by more precise spatial and temporal placement within the body thereby reducing both the size and
number of doses.
Transdermal drug delivery system is defined as the topically administered medications in the form of patches which when
applied to the skin deliver the drug, through the skin at a predetermined and controlled rate. The Transdermal device is a membranemoderated system. The membrane in this system is a microporous polypropylene film. The drug reservoir is a solution of the drug in a
mixture of mineral oil and polyisobutylene. This study release is maintained over a three-day period. Transdermal patches are
delivered the drug through the skin in controlled and predetermined manner in order to increase the therapeutic efficacy of drug and
reduced side effect of drug. Controlled drug release can be achieved by transdermal drug delivery systems (TDDS) which can deliver
the drug via the skin portal to systemic circulation at a predetermined rate over a prolonged period of time. For effective Transdermal
drug delivery system, the drugs are easily able to peneterate the skin and easily reach the target site. TDDS increase the patient
compliance and reduces the load as compared to oral route. FDA approved the first Transdermal system Transderm-SCOP in 1979, for
the prevention of nausea and vomiting associated with ravel, particularly by sea. Nicotin patch was the very first transdermal patch in
market of India.
Transdermal therapeutic systems are also defined as a self contained, discrete dosage forms which, when applied to the intact
skin, deliver the drug, through the skin at control rate to the systemic circulation. Transdermal formulation maintain drug
concentration within the therapeutic window for prolong period of time ensuring that drug levels neither fall below the minimum
effective concentration nor exceed the maximum effective concentration. Transdermal8 drug delivery systems are topically
administered medicaments. In the form of patches that deliver drugs for systemic effects at a predetermined and controlled rate.
A transdermal drug delivery device, which may be of an active or a passive design, is a device which provides an alternative route for
administering medication. Transdermal patches are flexible pharmaceutical preparation of varying sizes, containing, one or more
active ingredients. They are intended to be applied to the unbroken skin in order to deliver the active ingredient to the systemic
circulation after passing through the skin barriers.
These devices allow for pharmaceuticals to be delivered across the skin barrier. Theoretically, transdermal patches works in a
very simple way. A drug is applied in a relatively high dosage to the inside of patch, which is worn on the skin for an extended period
of time. Though a diffusion process, the drug enters the bloodstream directly though the skin.
Since there is high concentration on the patch and low concentration in the blood, the drug will keep diffusing into the blood; the drug
will keep diffusing into the blood for a long period of time, maintaining the constant concentration of drug in the blood flow.
Recently, the use of transdermal patches for pharmaceuticals has been limited because only a few drugs have proven to be
effectively delivered through the skin, typically cardiac drugs such as nitroglycerin and hormones such as estrogen. A skin patch uses
a special membrane to control the rate at which the liquid drug contained in the reservoir within the patch can pass through the skin
and into the bloodstream. The basic components of any transdermal delivery system include the drug(s) dissolved or dispersed in a
reservoir or inert polymer matrix; an outer backing film of paper, plastic, or foil, and a pressure-sensitive adhesive that anchors the
patch to the skin. The adhesive is covered by a release liner which needs to be peeled off before applying the patch to the skin. Drugs
administered via skin patches include scopolamine, nicotine, estrogen, nitroglycerin, and lidocaine. Transdermal delivery not only
provides controlled, constant administration of the drug, but also allows continuous input of drugs with short biological half-lives, and
eliminates pulsed entry into systemic circulation which often causes undesirable side effects.
Page
532
www.iajpr.com
Page
The phenomenon of percutaneous absorption can be visualized as a of series of steps in sequence, sorption of a molecule onto
the surface layer of stratum cornium, diffusion through it and various layers of epidermis. Finally at the papillary layer of dermis, the
molecule is taken up in to microcirculation for subsequent systemic distribution. The viable tissue layers and capillaries are relatively
permeable and peripheral circulation is sufficiently rapid.
533
www.iajpr.com
Figure no. 1: A multilayer skin model showing sequence of Transdermal permeation of drug for systemic delivery.
FACTORS THAT INFLUENCE TRANSDERMAL DELIVERY(5,6,7)
1. Biological parameters
2. Physicochemical parameters
Biological parameters:
Skin Condition:
The skin is a tough barrier to penetration, but only if it is intact. Vesicants such as acid, alkalis injure barrier cells and there
by promote penetration. In disease characterized by defective stratum cornium, percutenious absorption increases.
Blood flow:
Theoretically, changes in peripheral circulation, or blood flow through the dermis, could affect percutenious absorption. Thus
an increased blood flow could reduce time for whicha penetrant remain in the dermis and also raise the concentration gradient across
the skin.
Regional skin sites:
Variation in cutaneous permeability around the body depends on the thickness and the nature of stratum corneum and the
density of skin appendages. However rate of absorption at identical skin sites in different healthy volunteers varies.
Skin metabolism:
It has been recently reviewed the role which the skin plays in metabolism of drugs and steroidal hormones. The topical
bioavailability should account for not only skin permeation but also cutaneous drug metabolism.
Species differences:
Mammalian skin differs widely in characteristics such as horny layer thickness, sweat gland and hair follicle densities, and
pelt condition, the capillary blood supply and the sweating ability from species to species, so affect the permeation.
Physicochemical parameters:
Hydration of skin:
When water saturates the skin; tissue swells, softens and wrinkles and its permeability increases markedly. In fact, hydration
of stratum corneum is one of important factor in increasing the penetration rate of most substances that permeate the skin.
Page
Diffusion coefficient:
The diffusional speed of molecule depends mainly on state of matter in the medium. In gases and air, diffusion coefficients
are large because the void space available to the molecules is large as compared to their size.
534
Temperature:
The penetration rate of material through the human skin can change tenfold for large temperature variation, as the diffusion
coefficient decreases as the temperature falls. Occlusive vehicles increase skin temperature by few degrees, but any consequent
increased permeability is small compared to effect of hydration.
www.iajpr.com
Drug concentration:
The drug permeation usually follows the ficks law. The flux of solute is proportional to the concentration gradient across the
entire barrier phase.
Partition Coefficient:
Partition coefficient is important in establishing the flux of the drug through the stratum corneum. The balanced partition
coefficient is required for drug permeation.
Molecular size:
Absorption is apparently inversely related to molecular weight. Small molecule penetrates faster than large once.
TYPES OF TRANSDERMAL PATCHES(7,8,9)
Single layer drug in adhesive
In this type the adhesive layer contains the drug. The adhesive layer not only serves to adhere the various layers together and
this type of layer is responsible for the releasing the drug to the skin. The adhesive layer is surrounded by a temporary liner and a
backing.
Vapour patch
In this type of patch the role of adhesive layer not only serves to adhere the various layers together but also serves market,
commonly used for releasing of essential oils in decongestion. Various other types of vapour patches are also available in the market
which are used to improve the quality of sleep and reduces the cigarette smoking conditions.
Page
535
Reservoir system
In this system the drug reservoir is embedded between the two layers; an impervious backing layer and a rate controlling membrane.
The drug releases only through the rate controlling membrane, which can be micro porous or non porous. In the drug reservoir
compartment, the drug can be in the form of a solution, suspension, gel or dispersed in a solid polymer matrix. Hypoallergenic
adhesive polymer can be applied as outer surface polymeric membrane which is compatible with drug.
www.iajpr.com
Matrix system
Drug-in-adhesive system
In this type the drug reservoir is formed by dispersing the drug in an adhesive polymer and then spreading the medicated
adhesive polymer by solvent casting or melting on an impervious backing layer. On top of the reservoir, unmediated adhesive polymer
layers are applied for protection purpose.
Matrix-dispersion system
In this type the drug is dispersed homogenously in a hydrophilic or lipophilic polymer matrix. This drug containing polymer
disk is fixed on to an occlusive base plate in a compartment fabricated from a drug impermeable backing layer. Instead of applying the
adhesive on the face of the drug reservoir, it is spread along with the circumference to form a strip of adhesive rim.
Microreservoir system
In this type the drug delivery system is a combination of reservoir and matrix-dispersion system. The drug reservoir is formed
by first suspending the drug in an aqueous solution of water soluble polymer and then dispersing the solution homogeneously in a
lipophilic polymer to form thousands of unreachable, microscopic spheres of drug reservoirs. This thermodynamically unstable
dispersion is stabilized quickly by immediately cross-linking the polymer in situ by using cross linking agents.
Page
Backing membrane:
Backing Membrane should be flexible and should provide a good bond to reservoir. It should be impermeable to the drug.
Polymers like LDPE, LLDPE, MDPE and polyurethane are used in backing membrane. Membrane can be mono layer or multilayered.
536
Membrane:
Membrane controls the release of the drug from the reservoir and multi-layer patches. It may or may not be rate-controlling
membrane. It should be flexible enough not to split or crack on bending or stretching. Some of rate-controlling membranes are
polyethylene sheets, ethylene vinyl acetate copolymer, and cellulose acetate.
www.iajpr.com
Other exicipents:
Penetration enhancers:
These are compounds, which promotes skin permeability by altering the skin as a barrier to the flux of a drug. Desirable
properties of penetration enhancers are as follows.
Pharmacologically inert.
Nontoxic, nonirritating and nonallergic.
Rapid onset of action, predictable and suitable duration of action for the drug used.
Following removal of the enhancer, the stratum corneum should immediately and fully remover its normal barrier property.
The barrier function of the skin should decrease in one direction only and flux of endogenous materials should not occur.
Chemically and physically compatible with the delivery system.
Readily incorporated in to the delivery system.
Inexpensive and cosmetically acceptable.
Examples: Dimethyl sulfoxide (DMSO), N, N-Dimethylformade (DMF),Pyrrilidones,
Tetrahydrofurfuryl alcohol (THFA).
Solvents:
Alcohols and ethanol, in particular have been proposed as effective permeation enhancer. Examples: Acetamide and
derivatives, acetone, Dimethyl acetamide, Diethyl acetamide, Ethanol.
Surfactant:
These compounds are proposed to enhance substances polar transport, specific all hydrophilic drug. The ability of surfactant
to alter the penetration is a function of polar head group and hydrocarbon chain length. Commonly used surfactants are.
Anionic surfactants:
Dioctlysulthosuccinate, sodium lauryl sulfate, decodecylmethyl sulphoxaide.
Nonionic surfactants:
Pluronic F-127, pluronic F-66.
Bile salts:
Sodium taurocholate, sodium deoxycholate, sodium tauoglycocholate.
Page
537
Electroporation
Electroporation is a method of application of short, high-voltage electrical pulses to the skin. After electroporation, the
permeability of the skin for diffusion of drugs is increased by 4 orders of magnitude. The electrical pulses are believed to form
transient aqueous pores in the stratum corneum, through which drug transport occurs. It is safe and the electrical pulses can be
administered painlessly using closely spaced electrodes to constrain the electric field within the nerve-free stratum corneum.
www.iajpr.com
Application by ultrasound
Application of ultrasound, particularly low frequency ultrasound, has been shown to enhance transdermal transport of various
drugs including macromolecules. It is also known as sonophoresis. Katz et al. reported on the use of low-frequency sonophoresis for
topical delivery of EMLA cream.
Use of microscopic projection
Transdermal patches with microscopic projections called microneedles were used to facilitate transdermal drug transport.
Needles ranging from approximately 10-100 m in length are arranged in arrays. When pressed into the skin, the arrays make
microscopic punctures that are large enough to deliver macromolecules, but small enough that the patient does not feel the penetration
or pain. The drug is surface coated on the microneedles to aid in rapid absorption. They are used in development of cutaneous
vaccines for tetanus and influenza. Various other methods are also used for the application of the transdermal patches like thermal
poration, magnetophoresis, and photomechanical waves. However, these methods are in their early stage of development and required
further detail studying.
METHODS OF PREPARATION OF TRANSDERMAL PATCHES(15,16,17,18)
Transdermal drug delivery patches can be prepared by various methods:
Mercury Substrate Method:
In this method required amount of drug is dissolved in predetermined amount of polymer solution along with plasticizer. The
above solution is to be stirred for some time to produce a homogenous dispersion and it is keep aside until air bobbles removed
completely and then poured in to a glass ring which is placed over the mercury surface in a glass petridish. The rate of evaporation of
the solvent is controlled by placing an inverted funnel over the petridish. The dried films are to be stored in desiccators.
Circular Teflon Mould Method:
Solutions containing polymers in various ratios are used in an organic solvent. Calculated amount of drug is dissolved in half
the quantity of same organic solvent. Plasticizer added into drug polymer solution. The total contents are to be stirred and then poured
into a circular teflon mould. And rate of solvent vaporization controlled with placing inverted glass funnel on teflon mould. The
solvent is allowed to evaporate for 24 hrs. The dried films are to be stored in desiccators.
Glass Substrate Method:
The polymeric solutions are kept a side for swelling then required quantity of plasticizer and drug solution are added and
stirred for 10 min. Further, it is set-a side for some time to exclude any entrapped air and is then poured in a clean and dry anumbra
petriplate. The rate of solvent evaporation is controlled by inverting a glass funnel over the petriplate. After over night, the dried films
are taken out and stored in desiccators.
By Using IPM Membranes Method:
In this method drug is dispersed in a mixture of water and propylene glycol containing carbomer 940 polymers and stirred for
12 hrs in magnetic stirrer. The dispersion is to be neutralized and made viscous by the addition of triethanolamine. Buffer pH 7.4 can
be used in order to obtain solution gel, if the drug solubility in aqueous solution is very poor. The formed gel will be incorporated in
the IPM membrane.
By Using EVAC Membranes Method:
In order to prepare the target transdermal therapeutic system, 1% carbopol reservoir gel, polyethylene (PE), ethylene vinyl
acetate copolymer (EVAC) membranes can be used as rate control membranes. If the drug is not soluble in water, propylene glycol is
used for the preparation of gel. Drug is dissolved in propylene glycol; carbopol resin will be added to the above solution and
neutralized by using 5% w/w sodium hydroxide solution. The drug (in gel form) is placed on a sheet of backing layer covering the
specified area. A rate controlling membrane will be placed over the gel and the edges will be sealed by heat to obtain a leak proof
device.
www.iajpr.com
Page
538
Then the drug adhesive components and excipients are mixed with a solvent to achieve uniform solution. These adhesive
composition are deposited as a thin film on moving substances rate which are subsequently dried to remove solvent. Then lamination
of the dried adhesive film and other layer to form the five layer product consisting of release linear contact adhesive control
membrane, drug reservoir and backing substrate. The lamination then printed and die cut into final dosage form. The production are
then packed in individual foil pouches. After inspection the products are automatically inserted into a continuously moving web of
pouch stock which is sealed around the dosage form.
www.iajpr.com
Page
539
Drying Unit
Closed to the environment and is directly connected to the drying unit to avoid solvent and this active agent evaporation. The
solvent is evaporated from the adhesive mars by running the coated web through a drying channel using a transport system like
cranked shaft, conveyor belt.
Packaging
Primary packaging is done using sealed, four cornered while secondary packaging in cardboard boxes precedes shipment.
Fig. 4: The process and equipment involved in the manufacture of an adhesive dispersion system.
Matrix diffusion controlled system
The drug is dispersed in an insoluble matrix of rigid non swellable hydrophobic material. Materials used for rigid matrix are
insoluble plastics such as PVC and fatty and materials like stearic and beewax. With the plastic materials the drug is generally
kneaded with the solution of Polyvinyl chloride in an organic solvent and granulated waxy matrix is prepared by dispersing the drug in
molten fat followed by congealing.
The granules are then compressed into tablets swellable matrix systems are popular for sustaining the release of highly water
soluble drug. The material for such matrices are generally hydrophilic gums and may be of natural origin (guar gum, tragacanth) semi
synthetic (HPMC, CMC) or synthetic (poly cryamides) The drug and the gum are granulated together with a solvent such as alcohol
and compressed into tablets. The release of drug from such initially dehydrated hydro gels involves simultaneous absorption of water
and desorption of drug via a swelling controlled diffusion mechanism. The gum swells and the drug diffuse out of it the swallen mars
devoid of drug appears transport.
Microsealed dissolutionControlled system or Encapsulation
The drug particles are coated or encapsulated by one of the several micro encapsulation techniques with slowly dissolving
materials like cellulose, PEGs, polymethacrylates, waxes. The resulting pellets may be filled as such in hard gelatin capsule. The
dissolution role of coat depends upon the solubility and thickness of the coating which may range from 1 to 200 microns.
TECHNOLOGIES FOR DEVELOPING TRANSDERMAL DRUG DELIVERY SYSTEMS(22,23,24,25)
The technologies can be classified in four basic approaches.
The drug molecules are released through the rate controlling membrane. In the drug reservoir component, drug is suspended
in viscous fluid that forms paste like suspension. The rate of drug release from this type of TDDS depends on polymer composition,
www.iajpr.com
Page
Figure no. 5: Cross-sectional views of polymer membrane permeation-controlled TDD systems and release rate obtained.
540
permeability coefficient and thickness of rate controlling membrane. The rate controlling membrane can be either a microporous or a
nonporous polymeric membrane. e.g. ethylene-vinyl acetate copolymer, with specific drug permeability e.g. Some US FDA approved
systems are Transderm-Nitro for angina pectoris, Transderm-Scop as an antiemetic.
B. Polymer matrix diffusion-controlled TDD systems:
Polymer matrix diffusion-controlled TDD systems formed by homogeneously dispersing the drug solids in a hydrophilic or
lipophilic polymer matrix, and then the medicated polymer is molded into medicated disks with defined surface area and thickness.
This drug reservoir containing polymer disk is then mounted on occlusive base plate in a compartment fabricated from a drugimpermeable plastic backing. Instead of coating adhesive polymer directly on the surface of medicated disk, it is applied along the
circumference of the patch to form a strip of adhesive rim surrounding the medicated disk-. e.g. Nitro-Dur system and NTS system for
angina pectoris. (Figure no. 7.).
www.iajpr.com
Page
541
glycol, then the drug suspension is homogeneously dispersed with lipophilic polymer, by high shear mechanical force, to form
thousands of unleachable microscopic drug reservoirs.e.g. Nitrodisk system for angina pectoris. Figure no. 9.
Tack properties
Tack is the ability of a polymer to adhere to a substrate with little contact pressure. It is depends on the molecular weight and
composition of polymer.Test of tack includes.
www.iajpr.com
Page
542
Page
543
www.iajpr.com
Page
544
www.iajpr.com
Page
545
Animal models
In Vivo animals models are preferred because considerable time and resources are required to carry out studies in humans.
Some of the species are used : mouse, rat, guinea pig, rabbit, rat, cat, dog, pig, house, monkey small hairy animals (e.g. rat, rabbit) or
rhesus monkey is most reliable or in vivo evaluation of transdermal patches standard radiotracer methodology used. The application
site is generally the abdomen which are the least hairy site on the animals body. The compound is applied after light clipper showing
of the site.
www.iajpr.com
Human models
Human subjects should give pertinent information with minimum risk to the subjects within responsible period. It is first
described by Fieldman and Maibach. They includes determination of percutaneous absorption by an indirect method of measuring
radioactivity in excreta following topical application of the labeled drug. 14C is generally used for radio labeling. Determination of
absorption following topical administration requires the investigator to know the amount of radioactivity retained in the body or
excreted by routes. The percentage of dose absorbed transdermally is then calculated as.
Page
546
Laser Doppler
This test is based upon the fact that as a laser light beam passes through a specimen. It is scattered when it impinges (strike or
fall against) upon either static structure or moving object. Light beam scattered in static tissue will not undergo any frequency shift
while those encountering moving object will. Doppler effect by illuminating the skin with a monochromatic laser light and
electronically process. the frequency mix of the back scattered light collected by a photo editor system at the skin surface, a
continuous measure of the red cell flux. In the microvascular bed can be obtained. The irritation will lead to an increase in cutaneous
flow and thus increased red cell flux.
www.iajpr.com
www.iajpr.com
Page
REFERENCES
1. Ramteke KH, Dhole SN, Patil SV, Transdermal Drug Delivery System: A Review, J Adv Scient Res. 2012, 3(1), 22-35.
2. Sandipan Dass*, Satya Kinkar Dey, A novel approach towards transdermal drug delivery system: a precise review, Indo
American Journal of Pharmaceutical Research, 2013:3(6),213
3. Chien YW, Novel drug delivery systems, drugs and the Pharmaceutical sciences, Vol.50, Marcel Dekkar, New York, 1992, 797.
4. Kumar KJ, Suneetha KC, Uma devi SK, Sai Prasanthi N, Pravalika CH, Prasanna DL, Kalayan babu P, Venkateswarlu A, Brief
View of Antihypertensive drugs through Transdermal patches, JITPS. 2010, 1(7), 305-319.
5. Sharma A, Saini S and Rana AC, Transdermal Drug Delivery System: A Review, Int J Res Pharma Bio Sci, 4(1), 2013, 286-292.
6. Shiva Kumar HN, Vinay BL, Mulla JS, Jamakandi VG, Asian journal of pharmaceutics. 2009, 59-65.
7. Bharadwaj S, Garg VK, Sharma PK, Bansal M, Kumar N, Recent advancement in Transdermal drug delivery system,
International Journal of Pharma Professionals Research, 2011, 2(1), 247-254.
8. Kumar R, Philip A, Modified Transdermal Technologies: Breaking the Barriers of Drug Permeation via the Skin, Trop J Pharm
Res. 2007, 6(1), 633-644.
9. Guy RH, Current status and future prospects of transdermal drug delivery, Pharm Res. 1996, 13, 1765-1769.
10. Benson HAE, Transdermal Drug Delivery: Penetration Enhancement Techniques, Current Drug Delivery. 2005, 2, 23-33.
11. Guy RH, Hadgraft J, Bucks DA, Transdermal drug delivery and cutaneous metabolism, Xonobiotica. 1987, 7, 325-343
12. Sandhu Premjeet*, Ajay Bilandi, Kataria Sahil and Middha Akanksha IJRPC 2011, 1(4)
13. Chauhan B, Singh L, Chatterjee A, et al. An Approach Based on Advantages over Conventional System. Journal of Biomedical
and PharmaceuticalResearch. 2013; 2: 41-51.
14. Shalu Rani, Kamal Saroha, Navneet Syan, Transdermal Patches a successful tool in Transdermal Drug Delivery System: An
overview, Der Pharmacia Sinica, 2011, 2 (5), 17-29.
15. Nikhil Sharma, Geta Agarwal, Rana A.C, A Review Transdermal Drug Delivery System a tool for Novel Drug Delivery System,
IJDDR, 2011, 3 (3), 70.
16. Tanu Bhargava, Current trends in NDDS with special reference to NSAIDS, International Journal of Pharma and Bio Sciences,
2011, 2, 92-114
17. Eseldin Keleb, Rakesh Kumar Sharma, Transdermal Drug Delivery System-Design and Evaluation, International Journal of
Advances in Pharmaceutical Sciences, 2010, 1(3), 201-211.
18. Azhar Ahmed, Nirmal Karki, Rita Charde, Manoj Charde, Bhushan Gandhare, Transdermal Drug Delivery Systems, An
overview, International Journal of Biomedical and Advance Research, 2011, 02(01),38-56.
19. Parthasarathy G, Bhaskar reddy K and Prasanth V.V, Formulation and Characterization of Transdermal Patches of Naproxen with
various polymers, International Journal of Comprehensive Pharmacy , 2011, 6 (07), 1-3.
20. Bharkatiya M, Nema R.K, Bhatnagar M, Designing and Characterization of Drug free patches for Transdermal Application,
IJPSDR 2010, 2(1), 35-39.
21. Basavaraj K, Nanjwade, Kiran Suryadevara, Kella M.R and Sai Susmitha, Formulation and Evaluation of Transdermal Patches of
Ondansetron Hydrochloride using various polymers in different ratios, Current Trends In Biotechnology and Pharmacy, 2010, 4
(4), 917-921.
22. Pravin Gavali, Atul, Gaikwad, Radhika P.R, Sivakumar T, Design and Development of Hydroxypropyl Methylcellulose based
polymeric film of Enalapril Maleate, International Journal of Pharmtech Research, 2010, 2(1), 274-282.
23. Prabhu Prabhakara, Marina Koland, Preparation and Evaluation of Transdermal Patches of Papaverine Hydrochloride,
International Journal of Research Pharmaceutical Sciences, 2010,1(3), 259-266.
24. wikipedia.org/wiki/transdermal/patch/types
547
CONCLUSION
Tansdermal drug delivery system is useful for topical and local action of the drug. Transdermal Drug Delivery System a
realistic practical application as the next generation of drug delivery system.Transdermal drug delivery systems (TDDS) are dosage
forms involves drug transport to viable epidermal and or dermal tissues of the skin for local therapeutic effect while a very major
fraction of drug is transported into the systemic blood circulation. The adhesive of the transdermal drug delivery system is critical to
the safety, efficacy and quality of the product. Topical administration of therapeutic agents offers many advantages over conventional
oral and invasive methods of drug delivery. Several important advantages of transdermal drug delivery are limitation of hepatic first
pass metabolism, enhancement of therapeutic efficiency and maintenance of steady plasma level of the drug. This article provides
valuable information regarding the formulation and evaluation aspects of transdermal drug delivery systems. TDDS is a realistic
practical application as the next generation of drug delivery system.
25. www.noahhealth.org/pn/transdermal/patch/types
26. Grossberg GT, Sadowsky C, Olin JT. Rivastigmine Transdermal System for the Treatment of Mild to Moderate Alzheimers
Disease. Int J Clin Pract. 2010, 64(5): 651-660.
27. Samad, Ullah A, Alam Z, Wais M I, Shams M, Mohammad S. Transdermal Drug Delivery System: Patents Reviews. Recent Pat
Drug Deliv & formul 2009, 3(2):143-52
28. Pathan I Bashir, Setty C Mallikarjuna. Chemical Penetration Enhancers for Transdermal Drug Delivery Systems .Trop J Pharm
Res. 2009, 8 (2): 173-179.
29. Development,
fabrication,
&
evaluation
of
transdermal
drug
delivery
systema
review
http://www.pharmainfo.net/reviews/development-fabrication-and-evaluation-transdermal-drugdelivery-system-review. 20 may,
2012.
30. Aggarwal G, Development, Fabrication and Evaluation of Transdermal Drug Delivery A Review, Pharmainfo.net. 2009.
31. Shaila L, Pandey S and Udupa N, Design and evaluation of matrix type membrane controlled Transdermal drug delivery system
of nicotin suitable for use in smoking cessation, Ind J Pharm Sc. 2006, 68, 179-184.
32. Shingade GM, Quazi A, Sabale PM, Grampurohit ND, Gadhave MV, Jadhav SL, Gaikwad DD, Review on: Recent trend on
transdermal drug delivery system, Journal of Drug Delivery & Therapeutics. 2012, 2(1), 66-75.
33. Tipre ND &Vavia RP, Formulation Optimization and Stability Study of Transdermal Therapeutic System of Nicorandil, Informa
Healthcare. 2002, 7(3), 325-332.
34. Pawan Jalwal*1, Anju Jangra1, Lalita Dahiya1, Yashpal Sangwan2, Rajiv Saroha2 The Pharma Research (T. Ph. Res.), (2010), 3;
139-149.
Page
548
54878478451150133
www.iajpr.com